Until the turn of the century, treatment of hyperglycaemia in type 2 diabetes was limited to two main classes of drugs: sulphonylureas and biguanides. Though belonging to two distinct classes, these drugs shared two main characteristics: the first one is that they have been used to lower blood glucose much longer, before their mode of action could be understood; the second is that they both were the result of serendipitous discovery. In more recent years, through improved as it can occur in elderly people. VERIFY (NCT01528254) is a unique trial designed to determine durability, over a pre-specified 5-year follow-up, of early use of vildagliptin in combination with metformin in individuals at diagnosis or very short duration of disease and mild elevation of glycated haemoglobin (HbA1c). The results of the study will set the reference bar for any future clinical trial exploring early intensive treatment. INTERVAL (Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy) is the only study so far exploring the potential of DPP-4 inhibitors for target setting in elderly patients. These and all the other clinical studies are discussed in the following articles, providing the reader with all the elements for critical appreciation of vildagliptin as a valuable therapeutic option across the whole spectrum of the disease, i.e., from those with newly diagnosed diabetes to those progressively aging, as well as those living longer with their disease than they ever lived without diabetes.
